The American Psychiatric Association Council of Research Task Force on Novel Biomarkers and Treatments found that the data from 7 published placebo-controlled, double-blind, randomized clinical studies on Ketamine hydrochloride infusion therapy in the treatment of depression comprising 147 treated patients provide “compelling evidence that the antidepressant effects of ketamine infusion are both rapid and robust, albeit transient.” Reports of Ketamine’s unique antidepressant effects, combined with frequent media coverage promulgating the potential benefits of Ketamine treatment, have generated substantial interest and optimism among patients, families, patient advocacy groups, and clinicians alike. Read more about how Ketamine is used for treating depression. Source: American Medical Association